Cerenome (PSTV) Cash & Equivalents (2010 - 2026)

Plus Therapeutics (PSTV) has reported Cash & Equivalents for 17 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 69.37% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (down 69.37% YoY), while the FY2025 annual figure was $4.5 million, up 5821.05% from the prior year.
• Cash & Equivalents retreated to $3.0 million in Q1 2026 per PSTV's latest filing, from $4.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $21.2 million in Q1 2022 and bottomed at $74000.0 in Q1 2024.
• Historically, Cash & Equivalents has averaged $9.4 million across 5 years, with a median of $9.9 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 99.42% — and 2025, when it jumped 13233.78%.
• Plus Therapeutics' Cash & Equivalents stood at $18.1 million in 2022, then plunged by 52.79% to $8.6 million in 2023, then tumbled by 99.11% to $76000.0 in 2024, then soared by 5821.05% to $4.5 million in 2025, then sank by 32.84% to $3.0 million in 2026.
• Business Quant data shows PSTV's Cash & Equivalents at $3.0 million in Q1 2026, $4.5 million in Q4 2025, and $13.3 million in Q3 2025.